Axogen, Inc. (NASDAQ: AXGN) is a prominent player in the field of surgical technologies, focusing on peripheral nerve restoration. The company has recently achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its Biologics License Application (BLA) for AVANCE®, an acellular nerve allograft. This approval is crucial as it allows Axogen to treat both adult and pediatric patients with various peripheral nerve discontinuities.
On December 5, 2025, H.C. Wainwright set a price target of $39 for AXGN, suggesting a potential price increase of approximately 15.73% from its current price of $33.70. This optimistic outlook is likely influenced by the FDA's approval of AVANCE, which is expected to strengthen Axogen's market position. The approval, under the Accelerated Approval pathway, is based on positive effects observed in sensory nerve gaps, indicating a promising clinical benefit.
Currently, AXGN's stock is priced at $33.74, reflecting a 2.69% increase. The stock has risen by $0.885 today, with a trading range between $32.91 and $33.92. Over the past year, AXGN has experienced a high of $34.24 and a low of $9.22, showcasing its volatility. The company's market capitalization is approximately $1.55 billion, indicating its substantial presence in the market.
The FDA's approval of AVANCE is a pivotal development for Axogen, as it enhances the company's portfolio of innovative surgical solutions. This approval is expected to drive further interest in AXGN, potentially contributing to the stock reaching the $39 target set by H.C. Wainwright. The current trading volume of 470,115 shares on the NASDAQ exchange reflects the market's interest in Axogen's recent achievements.
